Geletneky, K., Hajda, J., Beelte, B., Capper, D., Bartsch, A. J., Neumann, J., . . . Unterberg, A. (2017). Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Molecular therapy, 25(12), . https://doi.org/10.1016/j.ymthe.2017.08.016
Chicago-Zitierstil (17. Ausg.)Geletneky, Karsten, et al. "Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial." Molecular Therapy 25, no. 12 (2017). https://doi.org/10.1016/j.ymthe.2017.08.016.
MLA-Zitierstil (9. Ausg.)Geletneky, Karsten, et al. "Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial." Molecular Therapy, vol. 25, no. 12, 2017, https://doi.org/10.1016/j.ymthe.2017.08.016.